The physical and digital biobank supports the integration of artificial intelligence in acute care diagnostics development.

The tests run on the company's TruVerus benchtop instrument, which provides results from a blood sample in minutes.

For full-year 2025, MDxHealth's preliminary revenues are $109 million, up 21 percent from 90.0 million in 2024. It billed 49,180 tissue-based units, up from 18 percent year over year, and 71,920 ...

The company said its preliminary revenues for the fourth quarter were at least $21 million, and its full-year 2025 revenues are expected to grow to $77 million.

The firm said it has appointed Abhishek Jain, a veteran of CareDx and Agilent Technologies, to be its next chief financial officer.

Last week, readers were most interested in a story about concerns about BillionToOne's Unity NIPT due to false negative results.

The company said that the sale of its medical device testing business would allow it to focus on core areas of preclinical drug development and chemical testing.

A recent blood-based hepatitis C virus assay on Nuclein's DASH system highlighted its on-device sample prep, among other features that have been driving its adoption.

The bill was one of several discussed during a Thursday hearing by the Health Subcommittee of the House of Representatives' ...

The companies will work to integrate Prevencio's protein-based blood tests into Quadrant's care pathways to better translate the results into clinical action and measure outcomes.

NEW YORK — Alpenglow Biosciences has partnered with digital pathology lab PathNet to develop 3D pathology-based diagnostics for prostate and bladder cancers, the companies said on Thursday.